Terminated PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT00954512

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

A Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination With Different Treatment Regimens in Subjects With Advanced Solid Tumors (Phase 1B/2; Protocol No. P04722)

Sponsor: Merck Sharp & Dohme LLC

Conditions Neoplasms

Interventions 5-FU Carboplatin Cetuximab Cisplatin Epirubicin Erlotinib Everolimus Folinic Acid Gemcitabine Irinotecan Paclitaxel Robatumumab Trastuzumab

Updated 9 times since 2017 Last updated: Jul 25, 2018 Started: Sep 25, 2009 Primary completion: Jun 7, 2011 Completion: Jun 7, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was terminated for business reasons.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Neoplasms trials with similar outcome

Browse all Neoplasms trials

Listed as NCT00954512, this PHASE1/PHASE2 trial focuses on Neoplasms and remains terminated or withdrawn. Sponsored by Merck Sharp & Dohme LLC, it has been updated 9 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2022 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jan 2021 — Jun 2022 [monthly]

Terminated PHASE1_PHASE2
Sep 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2

▶ Show 4 earlier versions

Jun 2018 — Sep 2018 [monthly]

Terminated PHASE1_PHASE2
Jul 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2
Feb 2017 — Jul 2017 [monthly]

Terminated PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1_PHASE2

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.